Sign in
SLDB Stock Price, Chart, Stats & News
Solid Biosciences Inc.
Save
Solid Biosciences Inc. (SLDB) does not currently pay a dividend.
690.71M
Market cap
–
Current P/E
–
Forward P/E
SLDB chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -74.97% |
ROE | -73.35% |
D/E | 0.12x |
Interest coverage ratio | -1400.05x |
SLDB valuation
P/E | – |
P/S | – |
P/B | 3.74x |
P/CF | -4.31x |
P/FCF | -3.52x |
P/OCF | -4.31x |
PEG | -0.33x |
EV multiple | -3.45x |
About
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Similar securities
Based on sector and market capitalization
Report issue